Posted by Michael Wonder on 01 Apr 2026
Orca Bio announces FDA review extension of BLA for Orca-T for the treatment of haematologic malignancies
1 April 2026 - Orca Bio today announced that the US FDA has extended the review timeline of its biologics license application for Orca-T for the treatment of patients with ahematologic malignancies.
The new PDUFA target action date is 6 July 2026.
